HHS Leadership Upheaval Could Delay Initiatives Impacting Biopharma
Secretary Price will be succeeded on an acting basis by HHS acting assistant secretary for health Donald Wright, and everything from development of the executive order on drug pricing to pending Medicare reimbursement experiments could see a pause as part of the transition.
You may also be interested in...
Scott Gottlieb claimed higher profile than most previous FDA commissioners with frequent Twitter posts and by including his remarks in many agency communications to industries and consumers. In his nearly two years in post, he also had more central role in FDA initiatives in areas such as keeping unsafe products labeled as supplements off the market and explaining why hemp and CBD are available and supplements even though FDA considers the products noncompliant as dietary ingredients.
President Trump has directed his new HHS Secretary to bring down drug prices – starting 2018 exactly the same way as 2017. But this time it could end differently.
Concerns with promoting competition and reducing consumers' 'pain in the pocketbook' are key tenets of the Trump Administration's approach to lowering prescription drug pricing, Grogan says.